Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DSGNOTCMKTS:JUSHFNASDAQ:NVCTNASDAQ:SOPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDSGNDesign Therapeutics$3.82-3.3%$3.87$2.60▼$7.77$224.24M1.62180,133 shs44,838 shsJUSHFJushi$0.30-3.3%$0.32$0.22▼$0.69$60.94M-1.1859,558 shs33,831 shsNVCTNuvectis Pharma$7.71-0.4%$9.17$4.44▼$11.80$161.72M-0.16129,287 shs166,813 shsSOPHSOPHiA GENETICS$3.10-2.2%$3.00$2.58▼$4.92$211.40M159,212 shs67,618 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDSGNDesign Therapeutics-3.29%+0.79%-1.55%-9.26%+18.27%JUSHFJushi+2.64%+2.71%-1.87%+7.04%-54.27%NVCTNuvectis Pharma-0.39%-4.22%-20.19%-26.29%+18.62%SOPHSOPHiA GENETICS-2.21%+1.97%+6.90%-4.91%-30.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDSGNDesign Therapeutics0.7094 of 5 stars1.01.00.00.03.32.50.6JUSHFJushi1.0158 of 5 stars0.03.00.00.02.91.70.6NVCTNuvectis Pharma2.9391 of 5 stars3.50.00.00.03.05.00.6SOPHSOPHiA GENETICS2.3099 of 5 stars3.43.00.00.03.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDSGNDesign Therapeutics 2.00Hold$4.004.71% UpsideJUSHFJushi 1.50ReduceN/AN/ANVCTNuvectis Pharma 3.00Buy$17.00120.49% UpsideSOPHSOPHiA GENETICS 2.67Moderate Buy$7.00125.81% UpsideCurrent Analyst Ratings BreakdownLatest JUSHF, SOPH, NVCT, and DSGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2025NVCTNuvectis PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $15.004/2/2025NVCTNuvectis PharmaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$17.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDSGNDesign TherapeuticsN/AN/AN/AN/A$4.28 per shareN/AJUSHFJushi$257.52M0.23N/AN/A($0.26) per share-1.15NVCTNuvectis PharmaN/AN/AN/AN/A$0.50 per shareN/ASOPHSOPHiA GENETICS$65.17M3.17N/AN/A$1.48 per share2.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDSGNDesign Therapeutics-$49.59M-$0.99N/AN/AN/AN/A-22.85%-22.02%8/4/2025 (Estimated)JUSHFJushi-$48.78M-$0.24N/AN/AN/A-18.54%N/A-10.71%8/6/2025 (Estimated)NVCTNuvectis Pharma-$19M-$1.13N/AN/AN/AN/A-148.83%-95.60%8/5/2025 (Estimated)SOPHSOPHiA GENETICS-$62.49M-$1.00N/AN/AN/A-98.51%-63.47%-40.06%8/5/2025 (Estimated)Latest JUSHF, SOPH, NVCT, and DSGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025DSGNDesign Therapeutics-$0.28-$0.31-$0.03-$0.31N/AN/A5/8/2025Q1 2025JUSHFJushi-$0.06-$0.09-$0.03-$0.09$66.23 million$63.85 million5/6/2025Q1 2025NVCTNuvectis Pharma-$0.30-$0.27+$0.03-$0.27N/AN/A5/6/2025Q1 2025SOPHSOPHiA GENETICS-$0.21-$0.26-$0.05-$0.26$16.76 million$17.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDSGNDesign TherapeuticsN/AN/AN/AN/AN/AJUSHFJushiN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDSGNDesign TherapeuticsN/A28.3728.37JUSHFJushiN/A1.130.57NVCTNuvectis PharmaN/A3.283.28SOPHSOPHiA GENETICS0.163.112.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDSGNDesign Therapeutics56.64%JUSHFJushi21.68%NVCTNuvectis Pharma96.77%SOPHSOPHiA GENETICS31.59%Insider OwnershipCompanyInsider OwnershipDSGNDesign Therapeutics31.20%JUSHFJushi22.48%NVCTNuvectis Pharma30.52%SOPHSOPHiA GENETICS4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDSGNDesign Therapeutics4056.77 million39.06 millionOptionableJUSHFJushi1,234196.63 million152.43 millionNot OptionableNVCTNuvectis Pharma820.89 million14.52 millionNot OptionableSOPHSOPHiA GENETICS52066.69 million63.43 millionNot OptionableJUSHF, SOPH, NVCT, and DSGN HeadlinesRecent News About These CompaniesAn end to an era: Supreme Court won't review IVF mixup rulingJune 26 at 1:00 PM | israelnationalnews.comIEnough hype about AI in health—let’s talk about resultsJune 12, 2025 | fastcompany.comFM42, AstraZeneca, and SOPHiA GENETICS launch UAE broad liquid biopsy initiative to transform cancer diagnosis and careJune 3, 2025 | zawya.comZM42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, careJune 3, 2025 | msn.comM42, partners launch liquid biopsy testing in UAEJune 3, 2025 | tradearabia.comTThe Multimodal Imperative: How AI-Driven Technology is Driving Impactful ChangesJune 2, 2025 | fiercepharma.comFSOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest UpdateJune 1, 2025 | marketbeat.com'An unusual precedent': Baby Sophia's genetic parents demand new Supreme Court hearingMay 28, 2025 | israelnationalnews.comIHigh Court grants custody of IVF baby to adoptive, not biological parentsMay 12, 2025 | msn.comSOPHiA GENETICS First Quarter 2025 Earnings: Revenues Beat Expectations, EPS LagsMay 12, 2025 | uk.finance.yahoo.comSupreme Court: IVF mixup baby to remain with birth parentsMay 12, 2025 | israelnationalnews.comISupreme Court upholds decision to keep IVF child with birth mother following embryo mix-upMay 12, 2025 | msn.comSupreme Court rules birth parents of child born in IVF mix-up are legal parentsMay 12, 2025 | msn.comThe Sophia Case: When Parenthood Isn’t Just About GeneticsMay 10, 2025 | blogs.timesofisrael.comBSOPHiA GENETICS SA (SOPH) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comSophia Genetics SA (SOPH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Improved ...May 7, 2025 | finance.yahoo.comSOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2025 | zacks.comSOPHiA GENETICS Reports First Quarter 2025 ResultsMay 6, 2025 | prnewswire.comSOPHiA GENETICS expands AstraZeneca liquid biopsy testApril 30, 2025 | investing.comSOPHiA GENETICS Expands AstraZeneca Partnership to Advance Liquid Biopsy WorldwideApril 29, 2025 | msn.comSOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACRApril 28, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJUSHF, SOPH, NVCT, and DSGN Company DescriptionsDesign Therapeutics NASDAQ:DSGN$3.82 -0.13 (-3.29%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$3.82 0.00 (0.00%) As of 06/26/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Jushi OTCMKTS:JUSHF$0.30 -0.01 (-3.29%) As of 06/26/2025 03:42 PM EasternJushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature's Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.Nuvectis Pharma NASDAQ:NVCT$7.71 -0.03 (-0.39%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$7.70 0.00 (-0.06%) As of 06/26/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.SOPHiA GENETICS NASDAQ:SOPH$3.10 -0.07 (-2.21%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$3.28 +0.18 (+5.81%) As of 06/26/2025 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
